首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1358031

抗體藥物複合體(ADC) 市場：按產品類型、按接頭類型、按用途、按配銷通路、按地區

Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography

出版日期: 2023年09月12日 | 出版商:

Coherent Market Insights | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球抗體藥物複合體（ADC）市場規模為53.8億美元，預計2030年將達到136.5億美元，在預測期間（2023-2030年）成長潛力巨大，年複合成長率為14.2%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	53.8億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	14.20%	2030年市場規模預測	136.5億美元

抗體藥物複合體(ADC)全球市場佔有率(%)（依產品類型），2023 年

抗體藥物複合體(ADC) 通常是透過化學接頭與細胞毒性藥物共用的單株抗體 (mAb)。 ADC結合了高特異性標靶能力和強殺傷作用的優點，能夠準確、有效率地消滅癌細胞，已成為抗癌藥物研發的熱點之一。自2000年美國食品藥物管理局（FDA）核准第一個ADC帕多塞布（吉妥珠單抗奧佐米星）以來，全球已有14個ADC核准。此外，超過 100 種 ADC 候選藥物目前正在臨床階段進行研究。抗體藥物複合體(ADC) 透過穩定的生物分解性接頭將高效細胞毒性抗癌藥物附著到單株抗體上，以區分癌症和正常組織。這些接頭可以是可裂解的或不可裂解的。連接體技術需要進步，將單株抗體與細胞毒性抗癌藥物結合、控制藥物藥物藥物動力學，並大幅改善細胞毒性藥物向癌細胞的傳遞。抗體標靶將標靶抗體-藥物綴合物與特定腫瘤抗原特異性結合，內化抗原-抗體複合物，並將標靶化療。

市場動態

用於癌症治療的新型 ADC 候選藥物的核准預計將支持預測期內的市場成長。例如，2023年2月3日，製藥公司吉利德科學公司獲得美國食品藥物管理局（FDA）批准，用於治療荷爾蒙受體（HR）陽性、人類表皮生長因子受體2（HER2）陰性患者無法手術的局部治療宣布核准Trodelvy (sacituzumab govitecan-hziy) 用於治療成年進行性或轉移性乳癌患者（IHC 0、IHC 1+ 或 IHC 2+/ISH-）。這些患者必須在轉移期之前接受過內分泌治療和至少兩次額外的全身性治療。

本次測試的主要特點

本報告對全球抗體藥物複合體（ADC）市場進行了詳細分析，並提出了以2022年為基準年的預測期（2023-2030）的市場規模和復合年度（年複合成長率）。
它還強調了各個細分市場的潛在收入成長機會，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球抗體藥物複合體(ADC) 市場的主要企業進行了分析。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出資訊的決策。
本研究報告針對該產業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球抗體藥物複合體（ADC）市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics（Suzhou）Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

第11章章節

參考
調查方法

簡介目錄

Product Code: CMI181

The global antibody drug conjugates market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to reach US$ 13.65 billion by 2030, exhibiting a CAGR of 14.2% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 5.38 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	14.20%	2030 Value Projection:	US$ 13.65 Bn

Global Antibody Drug Conjugates Market Share (%), By Product Type, 2023

Antibody Drug Conjugate (ADC) is typically made up of a monoclonal antibody (mAb) covalently attached to a cytotoxic drug via a chemical linker. It combines the advantages of highly specific targeting ability and a highly potent killing effect to achieve accurate and efficient elimination of cancer cells, making it one of the hotspots for anticancer drug research and development. Since the approval of the first ADC, Padcev (gemtuzumab ozogamicin) in 2000 by the U.S. Food and Drug Administration (FDA), till now 14 ADCs have been approved for market use worldwide. Furthermore, over 100 ADC candidates are currently being studied in clinical stages. Antibody-drug conjugates attach highly potent cytotoxic anticancer agents to monoclonal antibodies via biodegradable, stable linkers and discriminate between cancer and normal tissue. These linkers are either cleavable or non-cleavable. Linker technology advancements are required to attach monoclonal antibodies to cytotoxic anticancer agents, allowing control over drug pharmacokinetics and significantly improving cytotoxic agent delivery to cancer cells. The specific binding of the targeting antibody-drug conjugate to the specific tumor antigen and the internalization of the antigen-antibody complex to ensure focused delivery of the conjugated cytotoxic agent inside tumor cells are critical to the efficacy of antibody-targeted chemotherapy.

Market Dynamics

Approvals of novel ADC candidates for the treatment of cancer are anticipated to support the market growth over the forecasted period. For instance, on February 3, 2023, Gilead Sciences, Inc., a pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) granted approval for Trodelvy (sacituzumab govitecan-hziy) to be used in treating adult patients afflicted with inoperable locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-). These patients should have previously undergone endocrine-based therapy and received a minimum of two additional systemic therapies in the metastatic phase.

Key features of the study:

This report provides an in-depth analysis of the global antibody drug conjugates market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibody drug conjugates market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibody drug conjugates market

Detailed Segmentation:

By Product Type:
- Adcetris
- Kadcyla
- Enhertu
- Trodelvy
- Padcev
- Others (Blenrep, Tivdak, Zynlota, Elahere, etc.)
By Linker Type:
- Non-cleavable Linker
- Cleavable Linker
By Application:
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Others (Renal Caner, Urothelial & Bladder Cancer, etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics (Suzhou) Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Linker Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Antibody Drug Conjugates Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Antibody Drug Conjugates Market, By Product Type, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Adcetris
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Kadcyla
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Besponsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Lumoxiti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Mylotarg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Others (Polivy, Lumoxiti, Zynlonta, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

6. Global Antibody Drug Conjugates Market, By Linker Type, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Non-Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

7. Global Antibody Drug Conjugates Market, By Application, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Blood Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Breast Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Ovary Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Lung Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Skin Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Brain Tumor
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Others
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends

8. Global Antibody Drug Conjugates Market, By Distribution Channel , 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

9. Global Antibody Drug Conjugates Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- AstraZeneca PLC
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics (Suzhou) Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd